Hormones & Longevity: The Physician’s Guide to Hormonal Optimization After 40

Hormones & Longevity: The Physician’s Guide to Hormonal Optimization After 40

Conventional medicine typically addresses hormonal decline in one of two ways: either dismissing it as “normal aging” until symptoms become severe enough to require treatment, or treating it in isolation with a single hormone without understanding the broader hormonal ecosystem. Both approaches leave enormous longevity potential on the table.

In functional medicine, hormones are understood as an integrated network: sex hormones influence thyroid function; thyroid hormones influence insulin sensitivity; insulin levels influence sex hormone-binding globulin (SHBG) and free testosterone; cortisol competes with progesterone at receptor sites. Optimizing hormonal longevity requires understanding the whole network, identifying root-cause drivers of decline, and intervening with the minimum effective approach — lifestyle first, then targeted supplementation, then bioidentical hormone therapy when clinically indicated.

How Hormones Change with Age: The Decline Timeline

Hormonal aging does not proceed uniformly. Different hormones decline at different rates, through different mechanisms, with different health consequences:

Testosterone (men): Declines 1–2% per year after age 30, accelerating in the presence of metabolic syndrome, obesity, sleep apnea, and chronic stress. By age 70, average total testosterone is roughly 30–40% of peak. Critically, SHBG increases with age, reducing free (biologically active) testosterone even when total testosterone appears normal. Men with total testosterone of 450 ng/dL but SHBG of 65 nmol/L may have functional hypogonadism with free testosterone levels below 50 pg/mL.

Estradiol and progesterone (women): Perimenopause begins on average at age 47, with erratic fluctuations in estradiol and progressive progesterone decline. Full menopause (12 months without menstruation) occurs at an average age of 51. Estradiol falls 60–70% from peak during menopause; progesterone approaches zero. The vasomotor, cognitive, and metabolic consequences are now well-documented and no longer considered merely symptomatic — they are mechanistic drivers of accelerated cardiovascular risk, cognitive decline, and bone loss.

DHEA-S: Peaks at age 25 and declines continuously, reaching roughly 50% of peak by age 60 and 80–90% decline by age 80. DHEA is the precursor to both testosterone and estrogens and is produced almost entirely by the adrenal cortex. It has direct anti-glucocorticoid effects (opposing cortisol), neuroprotective properties, and immune-regulatory functions independent of its conversion to sex hormones.

Growth hormone (GH) and IGF-1: GH secretion falls by approximately 14% per decade after age 30. IGF-1 — which mediates most of GH’s anabolic effects — declines in parallel. While excessive GH/IGF-1 is associated with cancer risk and accelerated aging, deficient GH/IGF-1 drives sarcopenia, impaired recovery, visceral fat accumulation, and decreased quality of life. The goal is optimization, not maximization.

Testosterone: Men’s Primary Longevity Hormone

Consequences of Low Testosterone

Low testosterone — defined as total testosterone below 300 ng/dL by the American Urological Association, or free testosterone below 50–65 pg/mL by most functional medicine references — produces a well-characterized syndrome: reduced muscle mass and strength, increased visceral fat, insulin resistance, depression and reduced motivation, impaired cognitive function, reduced bone density, anemia, and elevated cardiovascular risk. A 2019 Circulation meta-analysis of 28 prospective studies found low testosterone independently associated with 25% higher cardiovascular mortality over 10–15 years.

Lifestyle-Driven Testosterone Optimization

Before considering TRT, lifestyle optimization can produce significant testosterone elevation. Resistance training — particularly compound movements at moderate-high intensity — produces acute testosterone elevation and, with consistent training, raises baseline levels by 10–25%. Sleep optimization is critical: a 2011 JAMA study found that 1 week of sleep restriction to 5 hours per night reduced testosterone by 10–15% in healthy young men. Weight loss of 10% body weight in obese men reliably increases testosterone by 60–100 ng/dL through SHBG reduction and improved Leydig cell function. Eliminating alcohol above 14 units/week, correcting vitamin D deficiency, and managing chronic stress are additional high-yield interventions.

Estrogen & Progesterone: Women’s Longevity Hormones

The Estrogen Longevity Paradox

The 2002 Women’s Health Initiative trial — which found increased breast cancer and cardiovascular risk with synthetic HRT (conjugated equine estrogens + medroxyprogesterone acetate) — generated decades of fear around estrogen therapy that was not fully warranted. Subsequent analysis showed that the risks applied specifically to older women (average age 63) starting HRT more than 10 years after menopause, and were associated with the synthetic progestin used, not with estradiol. The “timing hypothesis” — confirmed by multiple analyses — shows that women starting bioidentical hormone therapy within 10 years of menopause (or before age 60) have reduced cardiovascular events, reduced all-cause mortality, and reduced cognitive decline risk compared to women who receive no hormone therapy.

Estradiol (E2) — the primary biologically active estrogen — maintains vascular endothelial function, protects against insulin resistance, preserves bone density, supports cognitive function and memory, and reduces LDL-C while raising HDL-C. Its decline in menopause is directly responsible for the observed 2–4× increase in cardiovascular event rates in postmenopausal women compared to premenopausal women of the same age. Bioidentical estradiol (transdermal or vaginal, not oral) with micronized progesterone (Prometrium) is the evidence-based approach that avoids the risks of the original WHI synthetic hormones.

Thyroid Function: The Metabolic Master Regulator

The thyroid gland produces T4 (thyroxine, the storage form) and T3 (triiodothyronine, the active form) that regulate metabolic rate in virtually every cell of the body. Hypothyroidism — even subclinical hypothyroidism with TSH between 2.5–10 µIU/mL and normal T4 — produces fatigue, weight gain, cognitive slowing, elevated LDL-C, depression, constipation, and cold intolerance in many patients. The prevalence of subclinical hypothyroidism reaches 10–15% in adults over 60.

Beyond TSH: Why Standard Thyroid Testing Misses Dysfunction

Standard thyroid assessment uses TSH alone. This misses several common dysfunctions: elevated reverse T3 (rT3), which competes with active T3 at receptor sites and produces hypothyroid symptoms with normal TSH; inadequate T4-to-T3 conversion, which can occur in selenium deficiency, chronic inflammation, or high-stress states; and Hashimoto’s thyroiditis, an autoimmune thyroid disease affecting up to 10% of women, which requires TPO antibody and TG antibody testing for diagnosis. A comprehensive thyroid panel includes TSH, free T4, free T3, reverse T3, TPO antibodies, and TG antibodies. Normal TSH with low free T3 or elevated rT3 indicates functional hypothyroidism that standard screening will miss.

Nutrients Critical for Thyroid Function

Thyroid hormone synthesis and conversion require adequate iodine (150–220 mcg/day; excess above 500 mcg/day can paradoxically suppress thyroid function), selenium (55–200 mcg/day — critical for deiodinase enzymes that convert T4 to active T3), zinc (8–11 mg/day), and iron (required for thyroid peroxidase activity). Selenium deficiency is associated with both Hashimoto’s progression and impaired T4-T3 conversion. Brazil nuts (1–2 per day, not more) are an effective selenium source. Addressing these nutritional drivers is often sufficient to normalize subclinical thyroid dysfunction without thyroid medication.

DHEA, Cortisol & the Adrenal Axis

The DHEA:Cortisol Ratio as a Longevity Marker

DHEA and cortisol share the same adrenal precursor (pregnenolone) and are in metabolic competition. Chronic stress preferentially shunts pregnenolone toward cortisol production, depleting DHEA — a process called “pregnenolone steal.” The DHEA-S:cortisol ratio is an emerging longevity biomarker: high cortisol relative to DHEA is associated with accelerated immunosenescence, increased visceral fat, impaired glucose tolerance, and higher all-cause mortality in multiple cohort studies. Conversely, high DHEA-S relative to cortisol is a feature of exceptionally healthy aging populations. DHEA supplementation at 25–50 mg/day has shown improvements in mood, energy, immune function, and insulin sensitivity in older adults in multiple RCTs, with the strongest evidence in patients with documented DHEA-S deficiency below 75–100 µg/dL.

Cortisol: The Two-Edged Hormone

Cortisol is essential for life — it mobilizes glucose, suppresses inflammation acutely, and regulates the circadian clock. But chronically elevated cortisol (from chronic stress, poor sleep, or HPA axis dysregulation) drives visceral fat accumulation, insulin resistance, muscle catabolism, immunosuppression, hippocampal neuron damage, and accelerated telomere shortening. The goal is not to eliminate cortisol but to restore its normal circadian pattern: high in the morning (cortisol awakening response, or CAR), declining through the day, and low at night. Four-point salivary cortisol testing (morning, noon, afternoon, evening) reveals flattened, inverted, or dysregulated cortisol curves that explain symptoms that standard blood testing misses.

The Complete Hormonal Longevity Panel

A comprehensive hormonal longevity assessment for adults over 40 includes:

Sex hormones: Total testosterone, free testosterone (calculated or by equilibrium dialysis), SHBG, estradiol (E2), LH, FSH. For women: add progesterone (luteal phase timed, or any time if post-menopausal).

Thyroid: TSH, free T4, free T3, reverse T3, TPO antibodies, TG antibodies.

Adrenal: DHEA-S (serum), morning cortisol (serum), 4-point salivary cortisol (if HPA dysregulation suspected), pregnenolone.

Metabolic context: IGF-1, fasting insulin, HOMA-IR, fasting glucose/HbA1c, and hsCRP — because metabolic dysfunction is a primary driver of hormonal decline and treatment success depends on addressing the root cause.

Lifestyle Optimization Before Hormone Therapy

Before initiating any hormone replacement, the following lifestyle factors should be optimized — they collectively account for 30–60% of the hormonal decline in most middle-aged adults and often produce dramatic improvement without pharmaceutical intervention:

Sleep quantity and quality (7–9 hours, SWS-optimized). Growth hormone and testosterone are primarily released during slow-wave sleep. A single week of sleep restriction to 5 hours reduces testosterone by 15% and GH pulse amplitude by 50%. Sleep optimization is the single highest-ROI hormonal intervention available without a prescription.

Resistance training (3–4× per week). Progressive resistance training at 70–85% 1RM produces acute testosterone elevation and, chronically, upregulates androgen receptor density — meaning that even if testosterone levels remain the same, the hormonal signal becomes more effective. Strength training also suppresses SHBG through improved insulin sensitivity, increasing free testosterone.

Visceral fat reduction. Adipose tissue contains aromatase — the enzyme that converts testosterone to estradiol — and visceral fat is the most aromatase-dense depot. In obese men, aromatase overactivity creates a testosterone-to-estrogen imbalance that further suppresses LH production and creates a self-reinforcing cycle of testosterone decline. Every 10% reduction in body weight in metabolically obese men raises testosterone by 30–50 ng/dL.

Stress reduction and HRV optimization. Chronic cortisol elevation suppresses GnRH (gonadotropin-releasing hormone) at the hypothalamic level, reducing LH and FSH — the pituitary hormones that drive testosterone and estrogen production. Addressing chronic stress through HRV training, adequate Zone 2 exercise, mindfulness, and metabolic health optimization can recover 10–25% of the hormonal loss attributable to HPA dysregulation.

Frequently Asked Questions

What testosterone level is too low for men?

The AUA defines hypogonadism as total testosterone below 300 ng/dL with symptoms, but functional medicine practitioners often use a symptom-guided approach: men with total testosterone 300–450 ng/dL who have symptoms (fatigue, reduced libido, cognitive fog, loss of muscle/strength, depression) and low free testosterone (below 65 pg/mL) may benefit from intervention. The key is always to measure both total testosterone and free testosterone — SHBG elevation with age means total testosterone can appear normal while free testosterone is clinically low. I also measure LH and FSH to distinguish primary hypogonadism (testicular failure — high LH/FSH) from secondary hypogonadism (pituitary/hypothalamic suppression — low or normal LH/FSH), as the treatment approaches differ.

Is hormone replacement therapy safe for women?

For most women who are healthy, under 60, or within 10 years of menopause, bioidentical hormone therapy is safe and beneficial — reducing cardiovascular risk, cognitive decline, and osteoporosis when initiated early. The risk profile that generated concern in the 2002 WHI trial was specific to: synthetic progestins (medroxyprogesterone acetate, not micronized progesterone); oral (not transdermal) conjugated equine estrogens; women who were older (average age 63) and overweight; and delayed initiation more than 10 years post-menopause. The Menopause Society’s 2022 position statement concluded that for symptomatic women within the early initiation window, benefits exceed risks. Breast cancer risk with transdermal estradiol + micronized progesterone is not elevated above baseline in most analyses.

Should I test my hormones even if I feel fine?

Yes — for adults over 40, baseline hormonal assessment is valuable even in the absence of obvious symptoms. Hormonal decline is gradual and patients adapt to feeling suboptimal, normalizing fatigue, reduced libido, cognitive slowing, and reduced physical performance as “just aging.” Having a baseline panel at 40–45 provides reference values against which future changes can be measured — so a testosterone that drops from 650 to 380 ng/dL over 10 years is recognized as a 42% decline rather than dismissed because 380 ng/dL falls within the “normal range.” Context, trajectory, and symptom correlation together determine clinical significance.

What is the connection between insulin resistance and hormonal decline?

Insulin resistance drives hormonal decline through multiple pathways: elevated insulin reduces SHBG (paradoxically) in men and increases it in women; elevated insulin stimulates ovarian androgen production in women (polycystic ovary syndrome pathophysiology); insulin resistance promotes visceral fat accumulation and aromatase activity; and chronic hyperinsulinemia suppresses GH secretion. Conversely, optimizing insulin sensitivity through intermittent fasting, resistance training, and metabolic biomarker management produces downstream hormonal improvements that can partially substitute for hormone replacement therapy.

What is subclinical hypothyroidism and should it be treated?

Subclinical hypothyroidism (elevated TSH with normal T4, typically TSH 2.5–10 µIU/mL) is present in roughly 10% of adults over 65 and is associated with elevated LDL-C, impaired cardiac function, and cognitive slowing in multiple cohort studies. Treatment decisions are individualized: patients with TSH consistently above 5–7 µIU/mL plus symptoms (fatigue, weight gain, cognitive slowing, elevated cholesterol) and documented thyroid antibodies typically benefit from low-dose levothyroxine (25–50 mcg). Patients with TSH 2.5–5 µIU/mL and minimal symptoms may respond adequately to nutritional optimization (selenium, zinc, iodine) and monitoring rather than medication. The key is that subclinical hypothyroidism is not always benign — it should not be reflexively dismissed without symptom correlation and a trial of nutritional support.

Bottom Line

Hormonal decline after 40 is real, measurable, and consequential — contributing to sarcopenia, metabolic syndrome, cognitive decline, cardiovascular disease, and depression through well-characterized mechanisms. The approach is hierarchical: comprehensive panel first (total and free testosterone, SHBG, estradiol, progesterone, TSH/free T3/T4/rT3/antibodies, DHEA-S, morning cortisol, IGF-1), then lifestyle optimization (sleep, resistance training, visceral fat reduction, stress management), then nutritional support, then bioidentical hormone therapy when clinically indicated and lifestyle maximized.

The goal is not to chase 25-year-old hormone levels — it is to maintain the hormonal milieu required for metabolic health, cognitive function, cardiovascular protection, and physical capacity through the decades from 40 to 80+. Done with appropriate testing, monitoring, and lifestyle integration, hormonal optimization is one of the most impactful longevity interventions available in functional medicine.

Sources

• Leproult R, Van Cauter E. “Effect of 1 Week of Sleep Restriction on Testosterone Levels in Young Healthy Men.” JAMA. 2011. PMID: 21632481
• Maki PM, Henderson VW. “Hormone therapy, dementia, and cognition: the Women’s Health Initiative 10 years on.” Climacteric. 2012. PMID: 22612613
• The Menopause Society. “2022 Hormone Therapy Position Statement.” Menopause. 2022.
• Shores MM, Moceri VM, Gruenewald DA, et al. “Low testosterone is associated with decreased function and increased mortality risk.” J Am Geriatr Soc. 2004. PMID: 14728632
• Peng T, Qin J, Xiao X, et al. “Associations of testosterone levels with all-cause and cardiovascular mortality in men.” Circulation. 2019. Systematic review.
• Maggio M, Lauretani F, Ceda GP. “Sex hormones and sarcopenia in older persons.” Curr Opin Clin Nutr Metab Care. 2013. PMID: 23299708

Dive Deeper into Longevity

• Cognitive Health & Brain Longevity
• Mitochondrial Health & Longevity
• Gut Microbiome & Longevity
• The Evidence-Based Longevity Supplement Stack